10:24 AM EST - HempFusion Wellness Inc. : Announced that Mount Sinai Medical Hospital, New York City, has selected HempFusion CBD to be used as the exclusive brand and the sole supplier in a six-month clinical trial. The clinical trial, comprised of two studies, is being conducted by Dr. David Harnick , a board-certified cardiologist and electrophysiologist and Assistant Professor in Medicine and Cardiology at Mount Sinai, and is one of the first of its kind in the area of CBD’s effect on targeted cardiology markers. Dr. Harnick has constructed this long-term clinical trial to collect data that will assist in a deeper understanding of CBD’s effect on the body. He has chosen HempFusion for its rigors in regulatory standards, toxicology studies for safety and quality control adherence. The randomized, double-blinded, placebo-controlled trial is expected to begin in March 2021. HempFusion Wellness Inc.
shares T.CBD.U are trading up 5 cents at $2.70.
